10-12 September 2018 //  Lancaster Royal Hotel, London


James Noble

Mr James Noble

CEO, Adaptimmune Therapeutics

James has been involved with Adaptimmune's adoptive T cell therapy technology since 1999, when Avidex Limited (the predecessor company to Adaptimmune) was founded. He has over two decades of experience in biotechnology and has served on public and private boards of companies in the UK, the USA and Germany. He is currently Deputy Chairman at GW Pharmaceuticals plc, an AIM-listed biotech company, and is also a non-executive director on the Board of Immunocore, Adaptimmune's sister company, focused on soluble T cell receptor technology.

2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad